Stock SYRE SPYRE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
34.95 USD +2.64% Intraday chart for Spyre Therapeutics, Inc. +5.97% +62.41%
May. 15 Spyre Therapeutics, Inc. Announces Board Changes CI
May. 13 Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
PR
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
AQ
Spyre Therapeutics: Q1 Earnings Snapshot
AQ
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR
Spyre Therapeutics Announces Grants of Inducement Awards
AQ
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Spyre Therapeutics Announces Grants of Inducement Awards
AQ
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Spyre Therapeutics: Q4 Earnings Snapshot
AQ
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PR
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
PR
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn s and Colitis Organisation
AQ
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
AQ
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Spyre Therapeutics Announces Grants of Inducement Awards
PR
Spyre Therapeutics to Present at Upcoming Investor Conference
AQ
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
AQ
Aeglea BioTherapeutics : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
Aeglea BioTherapeutics Announces Grants of Inducement Awards
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYRE Stock
  4. News Spyre Therapeutics, Inc.
  5. Press Releases